Radiation can be a powerful cancer therapy, but it doesn’t work for everyone. A new study identifies tumor features linked with resistance to radiotherapy, an important advance toward developing individualized cancer treatments. In the study, published today in Nature Communications, a team led by UPMC Hillman Cancer Center researchers used mouse and lab-based human...
Latest News
Among some pediatric patients with acute lymphoblastic leukemia (ALL), several factors, including prephase dexamethasone and using total intravenous anesthesia during intrathecal therapy, are linked with improved central nervous system (CNS) control, according to research published in Blood. Overall survival (OS) rates have greatly improved among pediatric patients with ALL over the...
Boston, Mass. – Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer. But PD-1 functions can vary between different cell and cancer types, either promoting or...
Zürich, Switzerland – Sjögren’s disease is rare in children, and presenting symptoms differ from those seen in adults. For example, paediatric patients present less often with sicca complaints, and more frequently with parotid gland swelling and fever.1 This new work aimed to identify potentially dysregulated molecular pathways in children with...
BOSTON–A stem cell transplant (SCT) from a compatible donor early in the course of disease is the best approach for the majority of young and middle-aged adult patients with acute myeloid leukemia (AML), according to a new analysis of two dozen clinical studies. The findings of the study, published in...
BRISBANE, Calif. — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate TPST-1495, the company’s novel dual...
PORTLAND, Ore. and MUMBAI, India — A clinical study to validate the beta thalassemia (beta-thal) diagnostic capability of the Gazelle™ Hb Variant Test from Hemex Health, published in the journal Biosensors, showed that Gazelle correctly identified participating subjects with beta-thal major, beta-thal intermedia, and beta-thal trait with a combined accuracy...
SYDNEY – Australian pharmaceutical group Phebra (‘Company’) congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference. The abstract builds on the initial bioequivalence data from the first phase of the trial, published at EHA in June...
Chicago, Ill. Type 1 diabetes is an autoimmune disease that causes the body’s immune system to attack and destroy insulin-producing beta cells in the pancreas. Traditional management of type 1 diabetes has primarily involved replacing the missing insulin with injections which, though effective, can be expensive and burdensome. A new...
Maintenance therapy with olaparib was found to result in a clinically meaningful, but not statistically significant, improvement in overall survival compared with placebo among women with platinum-sensitive, BRCA 1/2-mutated, relapsed ovarian cancer, according to the results of a study published in The Lancet Oncology. Previously published results from the SOLO2/ENGOT-Ov21 trial (ClinicalTrials.gov Identifier: NCT01874353) demonstrated...